SCHEMBL4128685

SCHEMBL4128685

O=C(O)Cc1ccc(NC2=NC(=O)C(=Cc3ccc(C(F)(F)F)cc3)S2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
PTPN1 P18031 2/20 0.40
PTGDR2 Q9Y5Y4 5/20 0.39
PTPN22 Q9Y2R2 1/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
PPARG P37231 2/20 0.38
CFTR P13569 1/20 0.38
ALOX5 P09917 1/20 0.38
DUSP3 P51452 1/20 0.38
DUSP22 Q9NRW4 1/20 0.38
FFAR1 O14842 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4634822 1.00 PIM1 (0.41) PIM1PIM2PTPN1PTGDR2PTPN22
SCHEMBL4127838 0.88 PDE4B (0.42) PTPN22ALOX5DUSP3DUSP22FFAR1
SCHEMBL4127839 0.88 PDE4B (0.42) PTPN22ALOX5DUSP3DUSP22FFAR1
SCHEMBL4133860 0.87 DUSP22 (0.49) PTPN22ALOX5DUSP3DUSP22FFAR1
SCHEMBL4133862 0.87 DUSP22 (0.49) PTPN22ALOX5DUSP3DUSP22FFAR1
SCHEMBL4635275 0.85 ALOX5 (0.42) PTPN22ALOX5DUSP3DUSP22FFAR1
SCHEMBL4132445 0.85 FFAR1 (0.47) ALOX5DUSP3DUSP22FFAR1
SCHEMBL4132443 0.85 FFAR1 (0.47) ALOX5DUSP3DUSP22FFAR1
SCHEMBL4122528 0.84 ALOX5 (0.46) PTPN1PTPN22ALOX5DUSP3DUSP22
SCHEMBL4122531 0.84 ALOX5 (0.46) PTPN1PTPN22ALOX5DUSP3DUSP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ PIM1 1212/4885PIM2 1338/4885PTPN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.